Aclarion, Inc.

NasdaqCM ACON

Aclarion, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

Aclarion, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: ACON

Aclarion, Inc.

CEO	Mr. Brent Ness
IPO Date	April 22, 2022
Location	United States
Headquarters	951 Mariners Island Boulevard
Employees	4
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Database Medical Instruments Pharmaceuticals Software-as-a-Service (SaaS) Telehealth

Description

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Key trends

Past 5 years